Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven

Attard, Gerhardt, Reid, Alison H M, Yap, Timothy A, Raynaud, Florence, Dowsett, Mitch, Settatree, Sarah, Barrett, Mary, Parker, Christopher, Martins, Vanessa, Folkerd, Elizabeth, Clark, Jeremy, Cooper, Colin S, Kaye, Stan B, Dearnaley, David, Lee, Gloria and de Bono, Johann S (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology, 26 (28). pp. 4563-71. ISSN 1527-7755

Full text not available from this repository. (Request a copy)

Abstract

Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.

Item Type: Article
Uncontrolled Keywords: adenocarcinoma,administration, oral,aged,aged, 80 and over,androstenols,castration,disease progression,humans,male,middle aged,neoplasms, hormone-dependent,prospective studies,prostatic neoplasms,treatment outcome
Faculty \ School: Faculty of Science > School of Biological Sciences
Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 06 Jan 2014 14:16
Last Modified: 21 Apr 2020 22:32
URI: https://ueaeprints.uea.ac.uk/id/eprint/46147
DOI: 10.1200/JCO.2007.15.9749

Actions (login required)

View Item View Item